Source: Annual Congress 2004 - Management of lung cancer and innovative therapies
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Y. C. Kim, K. S. Kim, Y. I. Kim, S. C. Lim, C. M. Park, K. J. Na, S. J. Ahn, K. O. Park (Kwangju, South Korea). Predictors of response to ZD1839 (IressaÔ) in refractory non-small cell lung cancer. Eur Respir J 2004; 24: Suppl. 48, 1523

Member's Comments

No comment yet.

Related content which might interest you: Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Erlotinib as salvage treatment after failure to gefitinib in non-small cell lung cancer Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017 Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011 Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009 Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 Smoking habits and erlotinib response in non-small-cell lung cancer (NSCLC) treatment Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019